Home › Research › Treatments
Rates of Alzheimer disease biomarker positivity stratified by by sex and race in a specialty memory clinic
Anna Hofmann, Madeline Paczynski, Zachary J Posey, Melissa Aldinger, Tammie L.S. Benzinger, John C. Morris, B. Joy Snider, Suzanne Elizabeth Schindler. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract Background The Washington University Memory Diagnostic Center (MDC) in St. Louis, Missouri, annually sees approximately 4,000 patients with memory and thinking concerns and uses multiple biomarker modalities to assess for AD pathology, including to establish eligibility for anti‐amyloid treatments. We assessed the use of different biomarker modalities over time and the rates of biomarker positivity by sex and racial group. Method Biomarker positivity was based on the clinical interpretation of the Elecsys p ‐tau181/Aβ42 CSF test (Roche), the PrecivityAD and PrecivityAD2 blood tests (C2N Diagnostics), and Florbetaben or Florbetapir amyloid PET scans. Clinical and demographic data were retrospectively collected from electronic health records. Result A total of 970 patients were included who underwent at least one AD biomarker test between June 2021 and December 2024 at the MDC and/or anti‐amyloid treatment initiation. The average patient age was 71.5 ± 9.3 years (mean ± standard deviation), 51% were female, and 93% were White. The numbers of tests performed were as follows: 500 CSF tests, 290 amyloid PET scans, 143 PrecivityAD2 blood tests, and 87 PrecivityAD blood tests (Table 1). 50 patients underwent testing with more than one biomarker modality. The monthly volume of biomarker testing increased from ∼10 patients/month from July 2021‐July 2022 to ∼40 patients/month from July 2023‐July 2024 (Figure 1). Females were more likely than males to be biomarker positive: for CSF tests, 73% females and 65% males were positive, p = 0.041; for amyloid PET, 77% females and 67% males were positive, p = 0.045; for the PrecivityAD2 blood test, 82% females and 63% males were positive, p = 0.010 (Figure 2a). Only 42 individuals undergoing biomarker testing were Black (4%). White individuals were more likely than Black individuals to be biomarker positive on CSF tests (71% White and 35% Black were positive, p = 0.0018); few Black individuals underwent amyloid PET or blood tests (Figure 2b). Conclusion The MDC used a combination of CSF tests, blood tests, and amyloid PET scans to scale up AD biomarker testing over the past three years. Rates of AD biomarker positivity were approximately 70% across all three modalities, with females and White individuals having higher rates of positivity.
What this study adds
Evidence grade: Low
The record lists 4,000 participants. This study describes how a specialty memory clinic used different Alzheimer's disease biomarker tests over time and the rates of biomarker positivity by sex and racial group, based on 970 patients tested between June 2021 and December 2024. It is a description of testing patterns in one clinic and does not test any treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hofmann, A., Paczynski, M., Posey, Z. J., Aldinger, M., Benzinger, T. L., Morris, J. C., et al. (2025). Rates of Alzheimer disease biomarker positivity stratified by by sex and race in a specialty memory clinic. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_105627
Vancouver
Hofmann A, Paczynski M, Posey ZJ, Aldinger M, Benzinger TL, Morris JC, et al. Rates of Alzheimer disease biomarker positivity stratified by by sex and race in a specialty memory clinic. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_105627.
BibTeX
@article{hofmann2025-d8ce6554,
author = {Hofmann, Anna and Paczynski, Madeline and Posey, Zachary J and Aldinger, Melissa and Benzinger, Tammie L.S. and Morris, John C. and Snider, B. Joy and Schindler, Suzanne Elizabeth},
title = {{Rates of Alzheimer disease biomarker positivity stratified by by sex and race in a specialty memory clinic}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_105627},
url = {https://doi.org/10.1002/alz70856_105627}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Result A total of 970 patients were included who underwent at least one AD biomarker test between June 2021 and December 2024 at the MDC and/or anti‐amyloid treatment initiation.
Why it matters
This study describes how a specialty memory clinic used different Alzheimer's disease biomarker tests over time and the rates of biomarker positivity by sex and racial group, based on 970 patients tested between June 2021 and December 2024. It is a description of testing patterns in one clinic and does not test any treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants4,000
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 4,000 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Suzanne Elizabeth Schindler: h-index 56 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
187 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.